Neumora Therapeutics (NMRA) Assets Average (2023 - 2026)
Neumora Therapeutics' quarterly Assets Average came in at $172.5 million in Q1 2026, down 39.88% year-on-year from $286.9 million in Q1 2025, and down 6.49% quarter-over-quarter from $184.4 million in Q4 2025.
Neumora Therapeutics has reported Assets Average for 4 years, with the latest figure at $172.5 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 39.88% year-over-year to $172.5 million; the trailing twelve-month figure through Mar 2026 stood at $172.5 million (down 39.88% YoY), and the FY2025 full-year result was $254.0 million, down 37.53% from the prior year.
- Assets Average for Q1 2026 stood at $172.5 million, down from $184.4 million in the prior quarter.
- The five-year high for Assets Average was $520.5 million in Q4 2023, with the low at $172.5 million in Q1 2026.
- Average Assets Average over 4 years is $321.9 million, with a median of $310.8 million recorded in 2024.
- Year-over-year, Assets Average tumbled 35.68% in 2024 and tumbled 46.94% in 2025.
- Tracing NMRA's Assets Average over 4 years: stood at $520.5 million in 2023, then plunged by 35.68% to $334.8 million in 2024, then plunged by 44.9% to $184.4 million in 2025, then dropped by 6.49% to $172.5 million in 2026.
- The last three Assets Average figures came in at $172.5 million (Q1 2026), $184.4 million (Q4 2025), and $200.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | 172.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 172.46 Mn |
| Dec 31, 2025 | 184.44 Mn |
| Sep 30, 2025 | 200.83 Mn |
| Jun 30, 2025 | 240.29 Mn |
| Mar 31, 2025 | 286.86 Mn |
| Dec 31, 2024 | 334.75 Mn |
| Sep 30, 2024 | 378.51 Mn |
| Jun 30, 2024 | 427.34 Mn |
| Mar 31, 2024 | 473.20 Mn |
| Dec 31, 2023 | 520.47 Mn |